Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 396

Results For "SSI"

5598 News Found

Vacuubrand unveils new corporate identity
News | July 06, 2022

Vacuubrand unveils new corporate identity

VACUUBRAND has evolved rapidly in recent years, developing new innovative vacuum technology for laboratories, research and engineering


Apollo Hospitals integrates cardiovascular risk tool with ConnectedLife digital wellness solutions
Healthcare | July 06, 2022

Apollo Hospitals integrates cardiovascular risk tool with ConnectedLife digital wellness solutions

The AICVD tool can predict the risk of cardiovascular disease.


ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India
People | July 05, 2022

ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India

Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.


50% of heart attacks now happens in Indians below 50 years: says Expert
Public Health | July 05, 2022

50% of heart attacks now happens in Indians below 50 years: says Expert

Younger Indians have a 10 times higher rate of heart attack


Need for national-level awareness about organ transplant surgeries & organ donation in India
Healthcare | July 05, 2022

Need for national-level awareness about organ transplant surgeries & organ donation in India

People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.


OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212
Drug Approval | July 04, 2022

OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212

The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.


Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
Clinical Trials | July 04, 2022

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection


Pfizer submits new drug application to the U.S. FDA for Paxlovid
Drug Approval | July 03, 2022

Pfizer submits new drug application to the U.S. FDA for Paxlovid

Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk